{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:31Z","timestamp":1761871111029,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.clml.2017.09.013","type":"journal-article","created":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T03:01:22Z","timestamp":1506135682000},"page":"819-824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Role of Radiation in All Stages of Nodular Lymphocytic Predominant Hodgkin Lymphoma"],"prefix":"10.1016","volume":"17","author":[{"given":"Bismarck","family":"Odei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin","family":"Boothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Frandsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew M.","family":"Poppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David K.","family":"Gaffney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.09.013_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.013_bib2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.clml.2014.01.006","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma: biology, diagnosis and treatment","volume":"14","author":"Goel","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2017.09.013_bib3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A\u00a0revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.013_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0360-3016(94)E0136-8","article-title":"Lymphocyte predominant Hodgkin\u2019s disease: a clinicopathologic comparative study of histologic and immunophenotypic subtypes","volume":"31","author":"Crennan","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2017.09.013_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10428199709051786","article-title":"Nodular lymphocyte predominance Hodgkin\u2019s disease: long-term observation reveals a continuous pattern of recurrence","volume":"26","author":"Orlandi","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.09.013_bib6","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1200\/JCO.1997.15.9.3060","article-title":"Clinical presentation and outcome in lymphocyte-predominant Hodgkin\u2019s disease","volume":"15","author":"Bodis","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.013_bib7","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2004-02-0567","volume":"104","author":"Feugier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.013_bib8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin\u2019s lymphoma: patient outcomes from a large, single-institution series with long follow-up","volume":"28","author":"Chen","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.013_bib9","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin\u2019s disease and lymphocyte-rich classical Hodgkin\u2019s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin\u2019s Disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.013_bib10","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.013_bib11","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/1097-0142(19830615)51:12<2293::AID-CNCR2820511221>3.0.CO;2-X","article-title":"Hodgkin\u2019s disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin\u2019s lymphomas","volume":"51","author":"Miettinen","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.09.013_bib12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/asheducation-2006.1.266","article-title":"Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma","author":"Nogova","year":"2006","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2017.09.013_bib13","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome","volume":"118","author":"Savage","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.013_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00130404-200209000-00008","article-title":"Radiotherapy alone for lymphocyte-predominant Hodgkin\u2019s disease","volume":"8","author":"Schlembach","year":"2002","journal-title":"Cancer J"},{"key":"10.1016\/j.clml.2017.09.013_bib15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","article-title":"Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)","volume":"111","author":"Schulz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.013_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin\u2019s lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.09.013_bib17","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/cncr.10404","article-title":"European Organization for Research and Treatment of Cancer and Groupe d\u2019Etude des Lymphomes de l\u2019Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease","volume":"94","author":"Wilder","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.09.013_bib18","first-page":"1","article-title":"Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival","author":"Parikh","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.09.013_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0090-8258(83)90118-X","article-title":"Superficially invasive vulvar cancer with nodal metastases","volume":"15","author":"Hacker","year":"1983","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clml.2017.09.013_bib20","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clml.2017.09.013_bib21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2105\/AJPH.79.3.340","article-title":"Modeling and variable selection in epidemiologic analysis","volume":"79","author":"Greenland","year":"1989","journal-title":"Am J Public Health"},{"key":"10.1016\/j.clml.2017.09.013_bib22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma: a comprehensive analysis from the German Hodgkin Study Group","volume":"26","author":"Nogova","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.013_bib23","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood-2013-12-541078","article-title":"Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis","volume":"123","author":"Xing","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.013_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijrobp.2006.08.041","article-title":"Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin\u2019s lymphoma","volume":"67","author":"Aleman","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2017.09.013_bib25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.7326\/0003-4819-120-11-199406010-00002","article-title":"Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study","volume":"120","author":"Fabian","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2017.09.013_bib26","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.2009.26.0323","article-title":"Consolidation radiotherapy in patients with advanced Hodgkin\u2019s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519)","volume":"28","author":"Johnson","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.013_bib27","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group","volume":"104","author":"Wirth","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.09.013_bib28","doi-asserted-by":"crossref","unstructured":"Fanale MA. Outcomes of nodular lymphocyte predominant Hodgkin\u2019s lymphoma (NLPHL) patients treated with R-CHOP. Am Soc Hematol Annu Conf; December 5,\u00a02010.","DOI":"10.1182\/blood.V116.21.2812.2812"},{"key":"10.1016\/j.clml.2017.09.013_bib29","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S0002-9378(96)70654-3","article-title":"Sites of failure and times to failure in carcinoma of the vulva treated conservatively: a Gynecologic Oncology Group study","volume":"174","author":"Stehman","year":"1996","journal-title":"Am J Obstet Gynecol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016309260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016309260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:48Z","timestamp":1761870648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016309260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S2152265016309260"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.09.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Radiation in All Stages of Nodular Lymphocytic Predominant Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}